Država: Armenija
Jezik: engleski
Izvor: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
insulin human (recombinant DNA)
Novo Nordisk A/S
A10AC01
insulin human (recombinant DNA)
100IU/ml
suspension for injection
glass vial 10ml
Prescription
Registered
2019-06-13
COMBINATION OF THIAZOLIDINEDIONES AND INSULIN MEDICINAL PRODUCTS Cases of congestive heart failure have been reported when thiazolidinediones were used in combination with insulin, especially in patients with risk factors for development of congestive heart failure. This should be kept in mind if treatment with the combination of thiazolidinediones and insulin medicinal products is considered. If the combination is used, patients should be observed for signs and symptoms of congestive heart failure, weight gain and oedema. Thiazolidinediones should be discontinued if any deterioration in cardiac symptoms occurs. AVOIDANCE OF ACCIDENTAL MIX-UPS/MEDICATION ERRORS Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Insulatard® and other insulin products. INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION A number of medicinal products are known to interact with the glucose metabolism. THE FOLLOWING SUBSTANCES MAY REDUCE THE PATIENT’S INSULIN REQUIREMENT: Oral anti-diabetic products, monoamine oxidase inhibitors (MAOI), non-selective beta-blocking agents, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides. THE FOLLOWING SUBSTANCES MAY INCREASE THE PATIENT’S INSULIN REQUIREMENT: Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol. Beta-blocking agents may mask the symptoms of hypoglycaemia and delay recovery from hypoglycaemia. Octreotide/lanreotide may either increase or decrease the insulin requirement. Alcohol may intensify or reduce the hypoglycaemic effect of insulin. PREGNANCY AND LACTATION There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier. Both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death _in utero._ Intensified blood glucose control and monit Pročitajte cijeli dokument